Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal di...

-SEC Filing

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) ...

Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH...

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reasses...

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price tar...

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patie...

MU: 7% | Micron shares are trading higher after the company reported better-than-expected Q3 EPS and sales and issued strong Q4...

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety pr...

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Com...